Patents Assigned to Genecare Research Institute Co., Ltd.
  • Patent number: 10548990
    Abstract: Double-stranded modified siRNA targeting a RecQL1 helicase gene includes a sense strand including the nucleotide sequence shown in SEQ ID NO: 1, and an antisense strand including the nucleotide sequence shown in SEQ ID NO: 2, wherein the sense strand includes 2?-substituted nucleotides at positions 2, 3, 4 and 13 in the nucleotide sequence shown in SEQ ID NO: 1, the sense strand further includes a 2?-substituted nucleotide(s) at one or more positions selected from the group consisting of positions 12, 14, 17, 18 and 19 in the nucleotide sequence shown in SEQ ID NO: 1, wherein the position 2? of the 2?-substituted nucleotides is —R1, —OR1, —R2OR1, —OR2OR1 or —R3OR2OR1, wherein R1 represents a C1-4 alkyl group, and R2 and R3 independently represent a C1-3 alkylene group.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: February 4, 2020
    Assignee: GeneCare Research Institute Co., Ltd.
    Inventors: Kazunobu Futami, Yasuhiro Furuichi, Satoshi Kaneto
  • Patent number: 8809296
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: August 19, 2014
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Publication number: 20140179769
    Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.
    Type: Application
    Filed: February 26, 2014
    Publication date: June 26, 2014
    Applicant: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Patent number: 8703930
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: April 22, 2014
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20130245097
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Application
    Filed: May 22, 2013
    Publication date: September 19, 2013
    Applicant: GENECARE RESEARCH INSTITUTE CO., LTD.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Patent number: 8470798
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: June 25, 2013
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20130131331
    Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 23, 2013
    Applicant: GENECARE RESEARCH INSTITUTE CO., LTD.
    Inventor: GENECARE RESEARCH INSTITUTE CO., LTD.
  • Publication number: 20130090370
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Application
    Filed: September 27, 2012
    Publication date: April 11, 2013
    Applicant: GENECARE RESEARCH INSTITUTE CO., LTD.
    Inventor: Genecare Research Institute Co., Ltd.
  • Patent number: 8314073
    Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.
    Type: Grant
    Filed: November 17, 2005
    Date of Patent: November 20, 2012
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Patent number: 8299044
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: October 30, 2012
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Patent number: 8193332
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: June 5, 2012
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20110033858
    Abstract: PolydG is added to the terminal overhangs of an siRNA. Next, a primer containing a polydC sequence added with a tag sequence is annealed and cDNA is synthesized by a reverse transcription reaction. Quantitative PCR is performed between a primer carrying the same sequence as the tag sequence, and a primer containing the same sequence as the siRNA sequence to be detected. The amount of siRNA of interest can be determined from a calibration curve produced using known amounts of short-chain dsDNA.
    Type: Application
    Filed: January 29, 2009
    Publication date: February 10, 2011
    Applicant: GENECARE RESEARCH INSTITUTE CO., LTD.
    Inventors: Kazunobu Futami, Yasuhiro Furuichi
  • Publication number: 20100168209
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 1, 2010
    Applicant: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Publication number: 20090215867
    Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.
    Type: Application
    Filed: November 17, 2005
    Publication date: August 27, 2009
    Applicant: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Publication number: 20090028861
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Application
    Filed: April 8, 2005
    Publication date: January 29, 2009
    Applicant: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20070243570
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Application
    Filed: May 19, 2004
    Publication date: October 18, 2007
    Applicant: Genecare Research Institute Co., Ltd
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato